Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene appoints Steven Bloom as Chief Business Officer

Transgene appoints Steven Bloom as Chief Business Officer

Published 10 February 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade

Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade

Published 20 January 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Press release

Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors

Published 18 January 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene announces Financial Calendar for 2022

Transgene Announces Financial Calendar for 2022

Published 6 January 2022
Categorized as 2022, Press release

Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform

Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform

Published 15 December 2021
Categorized as 2021, 2021, Press release, Invir.IO, Press release, TG4050

Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine

Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine

Published 22 November 2021
Categorized as 2021, Press release, TG4050

Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

20211109 – Transgene BioInvent SITC BT-001 en

Published 9 November 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Transgene reports business update and Q3 2021 financial position

20211104 – Transgene – Q3 Financial update EN

Published 4 November 2021
Categorized as 2021, News-fr-en, Press release

Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021

BT-001 oncolytic virus at SITC 2021

Published 1 October 2021
Categorized as 2021, BT-001, Press release

Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023

Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023

Published 22 September 2021
Categorized as 2021, Press release, News-fr-en, Press release, TG4001, TG4001, TG6002 (FR)

Posts pagination

Newer posts Page 1 … Page 19 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu